Associate Professor at Cornell University, Weill Cornell Medical College
Oncology
Dr. Kristy L. Richards, MD
Kristy L. Richards, MD is an expert in the field of Oncology. He graduated from Stanford University School of Medicine. Stanford University School of Medicine is a top medical college. Stanford University School of Medicine is ranked 2 in research and 25 in primary care medicine Kristy Richards is also a published MD. He has 41 paper published. The most recent paper is: Inadequacy of the Gorlin formula for predicting prosthetic valve area.
Publications
- Stratifying diffuse large B-cell Lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
- Applied Protein and Molecular Techniques for Characterization of B Cell Neoplasms in Horses.
- Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell Lymphoma patients treated with rituxim...
- Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell Lymphoma.
- Lenalidomide-associated hemolytic Anemia.
- Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma.
- Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort.
- The genomic landscape of mantle cell Lymphoma is related to the epigenetically determined chromatin state of normal B cells.
- Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell Lymphoma (DLBCL) treated with immunochemotherapy: A report from the International ...
- Increased BCR responsiveness in B cells from patients with Chronic GVHD.
- Prevalence and Clinical Implications of Epstein-Barr Virus Infection in de novo Diffuse Large B-Cell Lymphoma in Western Countries.
- Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell Lymphoma patients treated with rituximab-CHOP.
- Clonally related composite follicular Lymphoma and mantle cell Lymphoma with clinicopathologic features and biological implications.
- MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell Lymphoma patients treated with rituximab-CHOP immunochemotherapy.
- Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy Era.
- Association of early HIV viremia with mortality after HIV-associated Lymphoma.
- Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell Lymphoma treated with rituximab-CHOP: a report from the International DLBCL Ritu...
- MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell Lymphoma and demonstrates high-risk gene expres...
- CD30 expression defines a novel subset of diffuse large B-cell Lymphoma with favorable prognosis and distinct gene expression signature: a report from The Internationa...
- Genetic heterogeneity of diffuse large B-cell Lymphoma.
- The genetic landscape of mutations in Burkitt Lymphoma.
- Complete Spontaneous Remission of Diffuse Large B-Cell Lymphoma of the Maxillary Sinus After Concurrent Infections.
- B cells from patients with Chronic GVHD are activated and primed for survival via BAFF mediated pathways.
- Further examination of BAFF SNPs in cGVHD.
- A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Patients with Refractory or Relapsed Acute Myeloid Leukemia.
- Clinical Presentation, Treatment, and Outcomes Among 65 Patients with HIV-Associated Lymphoma Treated at the University of North Carolina, 2000-2010.
- Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung Cancers.
- Protease-activated receptors mediate crosstalk between Coagulation and fibrinolysis.
- Lyn kinase-dependent regulation of miR181 and myeloid cell Leukemia-1 expression: implications for drug resistance in myelogenous Leukemia.
- Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion Lymphoma.
- Genome-wide hypomethylation in head and neck Cancer is more pronounced in HPV-negative tumors and is associated with genomic instability.
- Molecular signatures of metastasis in head and neck Cancer.
- Inadequacy of the Gorlin formula for predicting prosthetic valve area.
- Mitral valve prolapse in patients with prior rheumatic fever.
- Differing mechanisms of exercise flow augmentation at the mitral and aortic valves.
- Accuracy of mitral Doppler echocardiographic cardiac output determinations in adults.
- Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care.
- Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.
- Pharmacogenomic characterization of US FDA-approved cytotoxic drugs.
- FLT3 mutations in canine Acute lymphocytic leukemia.
Schools
Stanford University School Of Medicine
Harvard Med SchBrigham and Womens Hospital
University TxMD Anderson Cancer Center
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- American Republic
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- First Health (Coventry Health Care) PPO
- HealthSmart
- Choice Care PPO
- MedCost PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- United Healthcare
- Universal American
- Wells Fargo Insurance
Education
-
University of Texas Health Science Center -
Brigham and Women's Hospital -
Stanford University School of Medicine
Drug Facts
| NPI NUMBER | 1346349016 | |
| NPPES Provider LastName | RICHARDS | |
| NPPES Provider FirstName | KRISTY | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology | |
| Total Claim Count | 107.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1346349016 |
| Last Name Of The Provider | RICHARDS |
| First Name Of The Provider | KRISTY |
| View All |
Similar Doctors
|
Dr. Frank V. Fossella, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Janet E. Macheledt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yvonne H. Sada, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet C. Tu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan M. Escudier, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Ludwig IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anne Tsao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaoping Sun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Renata Ferrarotto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio C. Buzaid, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Yanyan Lou, MD |
|
Dr. Theodore F. Tenczynski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaohong I. Wang, MD |
|
|
Dr. Jenny V. Pozadzides, MD
This Doctor is OpenDoctor Recommended.
|